T0	Participants 61 130	metastatic or recurrent squamous cell carcinoma of the head and neck.
T1	Participants 381 530	recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients, whose disease has progressed after platinum-containing therapy.
T2	Participants 611 635	43 centers; 124 patients
T3	Participants 967 1089	A total of 121 patients were treated (61 afatinib, 60 cetuximab) and 68 crossed over to stage II (32 and 36 respectively).
T4	Participants 1904 1916	in R/M HNSCC